tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Keratosis, Actinic D055623 3 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Retrognathia D063173 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Scorpion Stings D065008 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kuo CJ et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. 1992 Nature pmid:1614535
Thomson AW et al. FK 506, cardiac transplantation, and graft-vessel disease. 1992 Lancet pmid:1370563
Japanese study of FK 506 on kidney transplantation: 2. Follow-up study of FK 506-treated patients. 1992 Transpl. Int. pmid:14621874
Walpoth B et al. Prevention of cardiac allograft rejection by FK506 and rapamycin: assessment by histology and nuclear magnetic resonance. 1992 Transpl. Int. pmid:14621877
Asako H et al. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. 1992 Transplantation pmid:1384191
Doi R et al. Effects of FK506 on exocrine pancreas in rats. 1992 Pancreas pmid:1372739
Kawano K et al. FK 506 ameliorates normothermic liver ischemia in rats by suppressing production of tumor necrosis factor. 1992 Transpl. Int. pmid:14621904
Furukawa H et al. The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. 1992 Transplantation pmid:1373531
Sakr M et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. 1992 Transplantation pmid:1373535
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Yamada K et al. New morphological changes induced by FK506 in a short period in the rat kidney and the effect of superoxide dismutase and OKY-046 on THEM: the relationship of FK506 nephrotoxicity to lipid peroxidation and change in production of thromboxane A2 in the kidney. 1992 Transpl. Int. pmid:14621878
Meingassner JG and Stütz A Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? 1992 J. Invest. Dermatol. pmid:1375617
Schneck FX et al. Pediatric renal transplantation under FK-506 immunosuppression. 1992 J. Urol. pmid:1375663
Connelly PR and Thomson JA Heat capacity changes and hydrophobic interactions in the binding of FK506 and rapamycin to the FK506 binding protein. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1375751
Lancaster JR et al. EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. 1992 J. Biol. Chem. pmid:1375934
Hirai T et al. The immunosuppressive effect of FK 506 on canine lung transplantation. 1992 J. Thorac. Cardiovasc. Surg. pmid:1375967
Tai PK et al. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. 1992 Science pmid:1376003
Jegasothy BV et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. 1992 Arch Dermatol pmid:1376102
de Paulis A et al. Anti-inflammatory effect of FK-506 on human skin mast cells. 1992 J. Invest. Dermatol. pmid:1281861
Wiederrecht G et al. Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1376117
Hasegawa S et al. Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation. 1992 J. Thorac. Cardiovasc. Surg. pmid:1279319
Peattie DA et al. Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1279700
Lhoëst G et al. Isolation and mass spectrometric identification of two metabolites of FK 506 from rat liver microsomal incubation media. 1992 Pharm Acta Helv pmid:1279730
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
Min DI et al. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. 1992 Am J Hosp Pharm pmid:1282779
Mochizuki M [Immunotherapy in ocular diseases]. 1992 Nippon Ganka Gakkai Zasshi pmid:1283052
Olejniczak ET et al. A 4D HCCH-TOCSY experiment for assigning the side chain 1H and 13C resonances of proteins. 1992 J. Biomol. NMR pmid:1283353
Bauer S et al. The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A. 1992 Int J Clin Pharmacol Ther Toxicol pmid:1283385
Renoir JM et al. [Effect of immunosuppressants FK506 and rapamycin on the function of progesterone receptor: protein "p59-HBI", intersection between immunology and endocrinology?]. 1992 C. R. Acad. Sci. III, Sci. Vie pmid:1284044
Natazuka T FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line. 1992 Kobe J Med Sci pmid:1284834
Tocci MJ and Sigal NH Recent advances in the mechanism of action of cyclosporine and FK506. 1992 Curr. Opin. Nephrol. Hypertens. pmid:1285380
Bavandi A et al. Diet-induced dermatitis response of hairless rats to systemic treatment with cyclosporin A (Sandimmun), cyclosporin H and FK506. 1992 Exp. Dermatol. pmid:1285411
Taki J et al. DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. 1992 Transplant. Proc. pmid:1379760
Sato Y et al. FK 506 suppresses class II antigen expression in regenerating livers following partial hepatectomy in the rat. 1992 Transplant. Proc. pmid:1379761
Stütz A Immunosuppressive macrolides. 1992 Transplant. Proc. pmid:1379762
Leiva MC and Lyttle CR Leukocyte chemotactic activity of FKBP and inhibition by FK506. 1992 Biochem. Biophys. Res. Commun. pmid:1379802
Iwasaki K et al. Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. 1992 Arzneimittelforschung pmid:1379812
Takada K et al. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. 1992 Biopharm Drug Dispos pmid:1379839
Lee TK et al. Mucosal glutamine utilization after small-bowel transplantation: an electrophysiologic study. 1992 J. Surg. Res. pmid:1382152
Kaye RE et al. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1382293
Edalji R et al. High-level expression of recombinant human FK-binding protein from a fusion precursor. 1992 J. Protein Chem. pmid:1382438
Thomson AW and Starzl TE FK 506 and autoimmune disease: perspective and prospects. 1992 Autoimmunity pmid:1382646
Christians U et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. 1992 Clin. Chem. pmid:1382896
Fruman DA et al. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. 1992 Eur. J. Immunol. pmid:1382988
Mittrücker HW and Fleischer B Functional localization of an exocytosis-triggering G-protein in human cytotoxic T lymphocytes. 1992 Immunology pmid:1383135
Xu RX et al. Stereospecific assignments and chi 1 rotamers for FKBP when bound to ascomycin from 3JH alpha,H beta and 3HN,H beta coupling constants. 1992 FEBS Lett. pmid:1377648
Petros AM et al. NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. 1992 J. Med. Chem. pmid:1377749
Strom TB Molecular immunology and immunopharmacology of allograft rejection. 1992 Kidney Int. Suppl. pmid:1383599
Wang SC et al. FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. 1992 J. Surg. Res. pmid:1383612
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Arai S et al. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. 1992 Jul-Aug J. Heart Lung Transplant. pmid:1379829
Fagiuoli S et al. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. 1992 Jul-Aug Ital J Gastroenterol pmid:1381245
Tong J et al. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. 1992 Jul-Aug Haematologica pmid:1385279
Nazer H et al. FK 506 associated disorders in liver transplantation. 1992 May-Jun J. Gastroenterol. Hepatol. pmid:1377038
Bowman H and Lennard TW Immunosuppressive drugs. 1992 Nov 4-17 Br J Hosp Med pmid:1282440
Sattler M et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. 1992 Sep-Oct Drug Metab. Dispos. pmid:1385058
Gibbs JF et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. 1993 Transplant. Proc. pmid:7679823
Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. 1993 Transplant. Proc. pmid:7679824
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Fukuzaki T et al. Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. 1993 Transplant. Proc. pmid:7680173
Schweizer M et al. Sensitivity of mitochondrial peptidyl-prolyl cis-trans isomerase, pyridine nucleotide hydrolysis and Ca2+ release to cyclosporine A and related compounds. 1993 Biochem. Pharmacol. pmid:7680201
Fischer S et al. A mechanism for rotamase catalysis by the FK506 binding protein (FKBP). 1993 Biochemistry pmid:7505615
Thomson AW et al. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. 1993 Autoimmunity pmid:7505632
Woodle ES et al. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. 1993 Transplant. Proc. pmid:7682360
López-Gil JA and García Sáiz M [FK506: an immunosuppressor for the '90's?]. 1993 Med Clin (Barc) pmid:7505871
Meiser BM et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. 1993 Transplant. Proc. pmid:7682363
Kagayama A et al. Oral absorption of FK506 in rats. 1993 Pharm. Res. pmid:7505939
Yu Y et al. Mutagenicity of the new immunosuppressive drugs, FK 506, and spergualin. 1993 Transplant. Proc. pmid:7682364
Rao PN et al. Prediction of early graft function by effluent levels of hyaluronic acid in clinical liver transplantation. 1993 Transplant. Proc. pmid:7682366
Keicho N et al. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. 1993 J. Antibiot. pmid:7693639
Iwasaki K et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. 1993 Res. Commun. Chem. Pathol. Pharmacol. pmid:7508138
Timerman AP et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. 1993 J. Biol. Chem. pmid:7693682
Schwaninger M et al. Inhibition of cAMP-responsive element-mediated gene transcription by cyclosporin A and FK506 after membrane depolarization. 1993 J. Biol. Chem. pmid:7693684
Smith DF et al. FKBP54, a novel FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. 1993 J. Biol. Chem. pmid:7693698
Soldin SJ et al. Immunophilin receptors for immunosuppressive drugs. 1993 Ther Drug Monit pmid:7510077
McMichael J et al. Computer-guided concentration-controlled trials in autoimmune disorders. 1993 Ther Drug Monit pmid:7510078
Lemster B et al. Blood lymphocytes of autoimmune disease patients receiving FK506 exhibit normal ex vivo cytokine gene expression and proliferative responses. 1993 Immunol. Lett. pmid:7510265
Parent SA et al. Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae. 1993 J. Gen. Microbiol. pmid:7510323
Ocain TD et al. A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase. 1993 Biochem. Biophys. Res. Commun. pmid:7685167
Asami M et al. Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. 1993 Biochem. Biophys. Res. Commun. pmid:7685169
Metcalfe S et al. Prodigiosin 25C: effect in in vitro models for T cell activation and T cell cycling and in vivo for rat heart allografts. 1993 Int. Arch. Allergy Immunol. pmid:7685216
Antoni FA et al. Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells. 1993 Biochem. Biophys. Res. Commun. pmid:7687429
Denesyuk AI et al. Comparison of conformations of cyclosporin A and macrolide FK506 fragments: localization of putative binding sites with phosphatase calcineurin. 1993 Biochem. Biophys. Res. Commun. pmid:7687433
Altmeyer A and Dumont FJ Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma. 1993 Cytokine pmid:7687472
Przepiorka D et al. Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. 1993 Bone Marrow Transplant. pmid:7687503
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Ohzato H et al. Serum interleukin-6 levels as an indicator of acute rejection after liver transplantation in cynomologous monkeys. 1993 Surg. Today pmid:7689373
Fesik SW NMR structure-based drug design. 1993 J. Biomol. NMR pmid:7689377
Lee KK et al. Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. 1993 Am. J. Surg. pmid:7678188
Galvin F et al. Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. 1993 Eur. J. Immunol. pmid:7678228
Foxwell BM et al. Inhibition of activation-induced changes in the structure of the T cell interleukin-7 receptor by cyclosporin A and FK506. 1993 Eur. J. Immunol. pmid:7678231